Zobrazeno 1 - 10
of 220
pro vyhledávání: '"Storozhakova, A."'
Autor:
A. A. Lyanova, L. Yu. Vladimirova, E. P. Ulyanova, N. A. Abramova, A. E. Storozhakova, I. L. Popova, N. M. Tikhanovskaya, M. A. Teplyakova, L. A. Ryadinskaya, I. A. Udalenkova, E. A. Kalabanova, S. N. Kabanov
Publikováno v:
Южно-Российский онкологический журнал, Vol 3, Iss 4, Pp 40-48 (2022)
Purpose of the study. An analysis of changes in the expression of the VEGF neoangiogenic factor in the tumor tissue of patients with squamous cell carcinoma of the oral mucosa receiving targeted therapy with cetuximab and chemotherapy.Patients and me
Externí odkaz:
https://doaj.org/article/aaad8131f37d45919c047248caac54d3
Autor:
L. Yu. Vladimirova, E. M. Frantsiyants, N. A. Abramova, K. A. Novoselova, V. S. Myagkova, O. V. Katelnitskaya, A. E. Storozhakova, I. L. Popova, S. N. Kabanov, N. M. Tikhanovskaya, E. A. Kalabanova, L. A. Ryadinskaya, A. A. Lyanova, M. A. Teplyakova, V. R. Zakharchenko, N. K. Guskova
Publikováno v:
Issledovaniâ i Praktika v Medicine, Vol 9, Iss 3, Pp 25-38 (2022)
Purpose of the study. An analysis of parameters of the blood coagulation system in breast cancer patients after coronavirus disease.Materials and methods. 50 breast cancer patients were divided into groups: the main group included 30 patients after c
Externí odkaz:
https://doaj.org/article/11865fec689245e7beb91d9a5389d4d9
Autor:
L. Yu. Vladimirova, N. A. Abramova, A. A. Lyanova, A. E. Storozhakova, I. L. Popova, M. A. Teplyakova, N. M. Tikhanovskaya, L. A. Ryadinskaya, E. A. Kalabanova, S. N. Kabanov, I. A. Udalenkova
Publikováno v:
Медицинский совет, Vol 0, Iss 9, Pp 117-125 (2022)
Introduction. Erythropoietin (EPO) application is a pathogenetic method for anemia correction in cancer patients.The purpose of study. Clinical evaluation of the efficacy and safety of Eralfon® (epoetin alpha) in treatment for anemia in patients wit
Externí odkaz:
https://doaj.org/article/0556a280772a4126b0e98abb8dd6c6c2
Autor:
L. Yu. Vladimirova, I. L. Popova, N. A. Abramova, M. A. Teplyakova, N. M. Tikhanovskaya, A. A. Lianova, A. E. Storozhakova, L. A. Ryadinskaya, S. N. Kabanov, E. A. Kalabanova
Publikováno v:
Медицинский совет, Vol 0, Iss 9, Pp 186-192 (2022)
The development of a new area of antitumor drug therapy, immunotherapy using immune checkpoint inhibitors targeting PD-1/PD-L1, has significantly changed approaches to the treatment of advanced non-small cell lung cancer (NSCLC). Many clinical trials
Externí odkaz:
https://doaj.org/article/85bf927f8c134ebfb917cdabd1d94338
Autor:
E. M. Frantsiyants, N. Yu. Samaneva, L. Yu. Vladimirova, A. E. Storozhakova, E. A. Kalabanova, S. N. Kabanov, A. V. Tishina
Publikováno v:
Южно-Российский онкологический журнал, Vol 2, Iss 3, Pp 6-12 (2021)
Purpose of the study. An analysis of blood levels of TGF-β, TGFR2, TNF-α, TNF-αR1, TNF-αR2, CD44 and MMP9 in patients with various biological subtypes of breast cancer receiving neoadjuvant chemotherapy.Materials and methods. This article present
Externí odkaz:
https://doaj.org/article/2fe7227ba9174294bd9da635b4d2499d
Autor:
L. Yu. Vladimirova, A. Eh. Storozhakova, I. L. Popova, S. N. Kabanov, N. A. Abramova, M. A. Teplyakova, N. M. Tikhanovskaya, K. A. Novoselova, A. A. Lyanova, L. A. Ryadinskaya, V. S. Myagkova, F. V. Alieva, E. A. Kalabanova, Ya. V. Svetitskaya, N. Yu. Samaneva, A. V. Tishina
Publikováno v:
Медицинский совет, Vol 0, Iss 9, Pp 64-74 (2021)
The development of a new direction in anticancer medical therapy – the use of immune checkpoint inhibitors targeting PD-1/ PD-L1 and CTLA-4 – has significantly changed the approach to tumor treatment in the last few years. The PD1 blocker nivolum
Externí odkaz:
https://doaj.org/article/d6b80369b6694d488584cf1468b3b89e
Autor:
Natalia I. Samaneva, Liubov I. Vladimirova, Irina V. Kolyadina, Elena M. Frantsiyants, Anna E. Storozhakova, Valeriya A. Bandovkina, Elena A. Kalabanova, Sergei N. Kabanov, Iana V. Svetitskaya, Anna V. Tishina, Mariia O. Ezhova
Publikováno v:
Современная онкология, Vol 23, Iss 1, Pp 82-87 (2021)
Relevance. Breast cancer (BC) is among the most common cancers and the leading causes of cancer death in women worldwide. Much attention is paid to the problem of its hormoneresistance; however, the issues of using prognostic markers and predictors i
Externí odkaz:
https://doaj.org/article/a9fdf814b2364cbe9492945661d48d9f
Autor:
Irina V. Kolyadina, Natalia R. Abidova, Arshak A. Akopyan, Galina V. Antonova, Oksana I. Arapova, Elvira A. Bobrova, Larisa V. Bolotina, Chulpan K. Valiakhmetova, Anna V. Vasilevskaya, Lyubov Y. Vladimirova, Mikhail V. Volkonskiy, Inna P. Ganshina, Irina E. Gudkova, Alexandr S. Dergunov, Irina V. Evstigneeva, Viktoria S. Egurenkova, Aleksei V. Emshanov, Lyudmila G. Zhukova, Elena V. Zueva, Elena V. Karabina, James J. Kolokolov, Svetlana V. Kuzmicheva, Olesya A. Kuchevskaya, Ivan A. Luev, Ksenia S. Maistrenko, Elena V. Markizova, Vasily V. Marfutov, Sergey P. Medvedev, Yulia I. Merzlikina, Tatyana A. Nersesova, Elena G. Ovchinnikova, Svetlana A. Orlova, Natalia Y. Samaneva, Olesya A. Stativko, Anna E. Storozhakova, Daniil L. Stroyakovskiy, Alexander V. Sultanbaev, Asiat I. Tekeeva, Natalia V. Fadeeva, Alina N. Fedorova, Oksana M. Shalaeva, Irina A. Shangina, Oksana N. Shirokova, Alisa R. Shumskikh, Mariam Z. Yakubova
Publikováno v:
Современная онкология, Vol 23, Iss 1, Pp 68-76 (2021)
Relevance. Data on the efficacy of endocrine and chemotherapy regimens in patients with hormone-resistant metastatic breast cancer (mBC) after progression with CDK4/6 inhibitors are limited; the search for an effective therapy regimen in this clinica
Externí odkaz:
https://doaj.org/article/714a7172db8b443795259379d343327b
Autor:
O. I. Kit, L. Yu. Vladimirova, E. A. Kalabanova, A. E. Storozhakova, S. N. Kabanov, T. A. Snezhko, I. S. Mitashok, Ya. V. Svetitskaya, N. Yu. Samaneva, I. S. Kornilova, Yu. V. Przhedetskiy, V. V. Pozdnyakova, N. A. Abramova, I. L. Popova, N. M. Tikhanovskaya, A. A. Lyanova, K. A. Novoselova, L. A. Ryadinskaya
Publikováno v:
Сибирский онкологический журнал, Vol 20, Iss 2, Pp 85-92 (2021)
Background. Breast cancer is one of the most common malignancies and one of the leading causes of cancer deaths among women in the Russian Federation. The prognosis of the disease is largely determined by thebiological subtype of the tumor. Her2-posi
Externí odkaz:
https://doaj.org/article/37520b7ab3864c81a9d042b834977f6f
Autor:
L. Yu. Vladimirova, A. E. Storozhakova, E. A. Kalabanova, P. N. Meshcheryakov, S. V. Oskin, S. N. Kabanov, N. Yu. Samaneva, Ya. V. Svetitskaya, A. V. Tishina
Publikováno v:
Южно-Российский онкологический журнал, Vol 2, Iss 1, Pp 35-42 (2021)
Lung cancer is among the most common malignant diseases in Russia. In 80–90%, its morphological type is nonsmall cell lung cancer. Stage IV primary advanced lung cancer is diagnosed in 41% of patients. Median overall survival in stage IV patients r
Externí odkaz:
https://doaj.org/article/076418e5fa3841ad91f9a0ffc47fbf9e